Summary of results for cyclosporine A therapy in patients with LGL leukemia
| No. of patients . | Treatment dosage . | Indication . | Time to response, % (wk) . | ORR . | Comments . | Reference (year) . |
|---|---|---|---|---|---|---|
| 3 | 600 mg/day | Anemia | 2-8 | 100 | CyA after steroid and Cytoxan failure | 73 (1996) |
| 5 | 2-3 mg/kg per day | Neutropenia/anemia | 3-9 | 100 | 1 CR achieved by adding GM-CSF | 74 (1998) |
| 25 | 5-10 mg/kg per day | Neutropenia/anemia | 9 | 56 | Response associated with DR4 phenotype 10 sustained responses; CR achieved by EPO | 67 (2003) |
| 23 | NR | Neutropenia/anemia | 2-60 | 78 | Response achieved by EPO | 65 (2006) |
| 9 | 225-350 mg/day | Neutropenia/anemia | 4-60 (4) | 40 | Response duration: on medications 9 months | 75 (2007) |
| 5 | 200 mg/day | PRCA (n = 5) | 2 | 25 | 2/5 relapses | 72 (2008) |
| 23 | NR | Neutropenia/anemia | NR | 44 | 16 as primary treatment | 13 (2009) |
| 10 | 2-3 mg/kg per day | PRCA (n = 2) | 11 | 70 | 3 CR after EPO/G-CSF | 66 (2010) |
| 6 | 100-150 mg/day | Neutropenia/anemia | NR | 50 | 2 dropout for SAE | 69 (2010) |
| 24 | 3-5 mg/kg per day | Neutropenia/anemia | 12-24 | 21 | 6 dropout for SAE | 12 (2010) |
| Total (n = 123) | 69/123 (56%) |
| No. of patients . | Treatment dosage . | Indication . | Time to response, % (wk) . | ORR . | Comments . | Reference (year) . |
|---|---|---|---|---|---|---|
| 3 | 600 mg/day | Anemia | 2-8 | 100 | CyA after steroid and Cytoxan failure | 73 (1996) |
| 5 | 2-3 mg/kg per day | Neutropenia/anemia | 3-9 | 100 | 1 CR achieved by adding GM-CSF | 74 (1998) |
| 25 | 5-10 mg/kg per day | Neutropenia/anemia | 9 | 56 | Response associated with DR4 phenotype 10 sustained responses; CR achieved by EPO | 67 (2003) |
| 23 | NR | Neutropenia/anemia | 2-60 | 78 | Response achieved by EPO | 65 (2006) |
| 9 | 225-350 mg/day | Neutropenia/anemia | 4-60 (4) | 40 | Response duration: on medications 9 months | 75 (2007) |
| 5 | 200 mg/day | PRCA (n = 5) | 2 | 25 | 2/5 relapses | 72 (2008) |
| 23 | NR | Neutropenia/anemia | NR | 44 | 16 as primary treatment | 13 (2009) |
| 10 | 2-3 mg/kg per day | PRCA (n = 2) | 11 | 70 | 3 CR after EPO/G-CSF | 66 (2010) |
| 6 | 100-150 mg/day | Neutropenia/anemia | NR | 50 | 2 dropout for SAE | 69 (2010) |
| 24 | 3-5 mg/kg per day | Neutropenia/anemia | 12-24 | 21 | 6 dropout for SAE | 12 (2010) |
| Total (n = 123) | 69/123 (56%) |
ORR indicates overall response rate; PRCA, pure red cell aplasia; NR, not reported; CyA, cyclosporine A; CR, complete response; GM-CSF, granulocyte-macrophage colony-stimulating factor; EPO, erythropoietin; G-CSF, granulocyte colony-stimulating factor; and SAE, serious adverse event.